Hui Shi1, Feng Yu2, Yinting Mao1, Qianqian Ju1, Yingcheng Wu3, Wen Bai3, Peiwen Wang3, Ran Xu3, Maorong Jiang4, Jiahai Shi1. 1. Department of Thoracic Surgery, Affiliated Hospital of Nantong University, Nantong 226001, China. 2. Institute of Life Sciences, Jiangsu University, Zhenjiang 212013, China. 3. Medical College, Nantong University, Nantong 226001, China. 4. Laboratory Animals Center, Nantong University, Nantong 226001, China.
Abstract
BACKGROUND: It is urgent to explore an effective potential therapeutic strategy for ESCC. In recent years, cell-based cancer immunotherapy has become a potentially close for carcinoma therapy. Chimeric antigen receptor (CAR) T cell technology is a kind of adoptive cell therapy technique which has been developed rapidly. We sought to obtain EphA2.CAR-T cell and revealed the ability of EphA2.CAR-T cells to kill esophageal squamous cell carcinoma (ESCC) cells in vitro. METHODS: Firstly, the expression and location of EphA2 in ESCC tissues and cells was tested by immunohistochemistry staining and Western blot. Secondly, the second generation of EphA2.CAR was constructed via molecular biology technology, and transduced into T cells to obtain the EphA2.CAR-T cell. The transduction efficacies were assessed using flow cytometry (FCM). Thirdly, the effect of cell killing of EphA2.CAR-T cell on ESCC cells in vitro was detected by co-culture experiments. The productions of cytokines (TNF-α and IFN-γ) by EphA2.CAR-T cell after co-culture with ESCC cells were analyzed by ELISA assay. RESULTS: The expression of EphA2 was significantly upregulated in ESCC tissues and cells (P<0.05). EphA2 was expressed on the membrane of ESCC cells, so it could be served as tumor-associated surface antigens (TAA) of CAR for ESCC treatment. The EphA2.CAR-T cell was obtained successfully, and its' transduction efficacies was 61.4% by FCM. The ability of cell killing of EphA2.CAR-T cell was better than that of T cells (P<0.01), and demonstrated a dose-dependent cell killing. The results of ELISA assay showed that the levels of TNF-α and IFN-γ in EphA2.CAR-T cells were notably raised compared with T cells (P<0.05). CONCLUSIONS: We firstly constructed the second generation of EphA2.CAR and established EphA2.CAR-T cells. The EphA2.CAR-T cells showed a dose-dependent cell killing of ESCC cells, and promoted the production of cytokines in vitro. These findings open a new way for treatment of ESCC by immunotherapy in the future.
BACKGROUND: It is urgent to explore an effective potential therapeutic strategy for ESCC. In recent years, cell-based cancer immunotherapy has become a potentially close for carcinoma therapy. Chimeric antigen receptor (CAR) T cell technology is a kind of adoptive cell therapy technique which has been developed rapidly. We sought to obtain EphA2.CAR-T cell and revealed the ability of EphA2.CAR-T cells to kill esophageal squamous cell carcinoma (ESCC) cells in vitro. METHODS: Firstly, the expression and location of EphA2 in ESCC tissues and cells was tested by immunohistochemistry staining and Western blot. Secondly, the second generation of EphA2.CAR was constructed via molecular biology technology, and transduced into T cells to obtain the EphA2.CAR-T cell. The transduction efficacies were assessed using flow cytometry (FCM). Thirdly, the effect of cell killing of EphA2.CAR-T cell on ESCC cells in vitro was detected by co-culture experiments. The productions of cytokines (TNF-α and IFN-γ) by EphA2.CAR-T cell after co-culture with ESCC cells were analyzed by ELISA assay. RESULTS: The expression of EphA2 was significantly upregulated in ESCC tissues and cells (P<0.05). EphA2 was expressed on the membrane of ESCC cells, so it could be served as tumor-associated surface antigens (TAA) of CAR for ESCC treatment. The EphA2.CAR-T cell was obtained successfully, and its' transduction efficacies was 61.4% by FCM. The ability of cell killing of EphA2.CAR-T cell was better than that of T cells (P<0.01), and demonstrated a dose-dependent cell killing. The results of ELISA assay showed that the levels of TNF-α and IFN-γ in EphA2.CAR-T cells were notably raised compared with T cells (P<0.05). CONCLUSIONS: We firstly constructed the second generation of EphA2.CAR and established EphA2.CAR-T cells. The EphA2.CAR-T cells showed a dose-dependent cell killing of ESCC cells, and promoted the production of cytokines in vitro. These findings open a new way for treatment of ESCC by immunotherapy in the future.
Authors: Kevin K H Chow; Swati Naik; Sunitha Kakarla; Vita S Brawley; Donald R Shaffer; Zhongzhen Yi; Nino Rainusso; Meng-Fen Wu; Hao Liu; Yvonne Kew; Robert G Grossman; Suzanne Powell; Dean Lee; Nabil Ahmed; Stephen Gottschalk Journal: Mol Ther Date: 2012-10-16 Impact factor: 11.454
Authors: Carmine Carpenito; Michael C Milone; Raffit Hassan; Jacqueline C Simonet; Mehdi Lakhal; Megan M Suhoski; Angel Varela-Rohena; Kathleen M Haines; Daniel F Heitjan; Steven M Albelda; Richard G Carroll; James L Riley; Ira Pastan; Carl H June Journal: Proc Natl Acad Sci U S A Date: 2009-02-11 Impact factor: 11.205
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Victoria M Youngblood; Laura C Kim; Deanna N Edwards; Yoonha Hwang; Pranav R Santapuram; Steven M Stirdivant; Pengcheng Lu; Fei Ye; Dana M Brantley-Sieders; Jin Chen Journal: Cancer Res Date: 2016-02-01 Impact factor: 12.701
Authors: Wolfgang Glienke; Ruth Esser; Christoph Priesner; Julia D Suerth; Axel Schambach; Winfried S Wels; Manuel Grez; Stephan Kloess; Lubomir Arseniev; Ulrike Koehl Journal: Front Pharmacol Date: 2015-02-12 Impact factor: 5.810
Authors: Lingfeng Liu; Daniel Sommermeyer; Alexandra Cabanov; Paula Kosasih; Tyler Hill; Stanley R Riddell Journal: Nat Biotechnol Date: 2016-02-22 Impact factor: 54.908